P1089: BRENTUXIMAB VEDOTIN, NIVOLUMAB, DOXORUBICIN, AND DACARBAZINE (AN+AD) FOR ADVANCED STAGE CLASSIC HODGKIN LYMPHOMA: PRELIMINARY SAFETY AND EFFICACY RESULTS FROM THE PHASE 2 STUDY (SGN35 027 PART B)

Detalles Bibliográficos
Autores principales: Lee, H., Flinn, I. W., Melear, J., Ramchandren, R., Friedman, J., Burke, J. M., Linhares, Y., Raval, M., Chintapatla, R., Feldman, T. A., Yimer, H., Islas-Ohlmayer, M., Dean, A., Rana, V., Gandhi, M. D., Renshaw, J., Gillespie-Twardy, A. L., Ho, L., Puhlmann, M., Guo, W., Yasenchak, C. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Posters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429456/
http://dx.doi.org/10.1097/01.HS9.0000847224.76139.00
_version_ 1784779448246075392
author Lee, H.
Flinn, I. W.
Melear, J.
Ramchandren, R.
Friedman, J.
Burke, J. M.
Linhares, Y.
Raval, M.
Chintapatla, R.
Feldman, T. A.
Yimer, H.
Islas-Ohlmayer, M.
Dean, A.
Rana, V.
Gandhi, M. D.
Renshaw, J.
Gillespie-Twardy, A. L.
Ho, L.
Puhlmann, M.
Guo, W.
Yasenchak, C. A.
author_facet Lee, H.
Flinn, I. W.
Melear, J.
Ramchandren, R.
Friedman, J.
Burke, J. M.
Linhares, Y.
Raval, M.
Chintapatla, R.
Feldman, T. A.
Yimer, H.
Islas-Ohlmayer, M.
Dean, A.
Rana, V.
Gandhi, M. D.
Renshaw, J.
Gillespie-Twardy, A. L.
Ho, L.
Puhlmann, M.
Guo, W.
Yasenchak, C. A.
author_sort Lee, H.
collection PubMed
description
format Online
Article
Text
id pubmed-9429456
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-94294562022-08-31 P1089: BRENTUXIMAB VEDOTIN, NIVOLUMAB, DOXORUBICIN, AND DACARBAZINE (AN+AD) FOR ADVANCED STAGE CLASSIC HODGKIN LYMPHOMA: PRELIMINARY SAFETY AND EFFICACY RESULTS FROM THE PHASE 2 STUDY (SGN35 027 PART B) Lee, H. Flinn, I. W. Melear, J. Ramchandren, R. Friedman, J. Burke, J. M. Linhares, Y. Raval, M. Chintapatla, R. Feldman, T. A. Yimer, H. Islas-Ohlmayer, M. Dean, A. Rana, V. Gandhi, M. D. Renshaw, J. Gillespie-Twardy, A. L. Ho, L. Puhlmann, M. Guo, W. Yasenchak, C. A. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9429456/ http://dx.doi.org/10.1097/01.HS9.0000847224.76139.00 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
spellingShingle Posters
Lee, H.
Flinn, I. W.
Melear, J.
Ramchandren, R.
Friedman, J.
Burke, J. M.
Linhares, Y.
Raval, M.
Chintapatla, R.
Feldman, T. A.
Yimer, H.
Islas-Ohlmayer, M.
Dean, A.
Rana, V.
Gandhi, M. D.
Renshaw, J.
Gillespie-Twardy, A. L.
Ho, L.
Puhlmann, M.
Guo, W.
Yasenchak, C. A.
P1089: BRENTUXIMAB VEDOTIN, NIVOLUMAB, DOXORUBICIN, AND DACARBAZINE (AN+AD) FOR ADVANCED STAGE CLASSIC HODGKIN LYMPHOMA: PRELIMINARY SAFETY AND EFFICACY RESULTS FROM THE PHASE 2 STUDY (SGN35 027 PART B)
title P1089: BRENTUXIMAB VEDOTIN, NIVOLUMAB, DOXORUBICIN, AND DACARBAZINE (AN+AD) FOR ADVANCED STAGE CLASSIC HODGKIN LYMPHOMA: PRELIMINARY SAFETY AND EFFICACY RESULTS FROM THE PHASE 2 STUDY (SGN35 027 PART B)
title_full P1089: BRENTUXIMAB VEDOTIN, NIVOLUMAB, DOXORUBICIN, AND DACARBAZINE (AN+AD) FOR ADVANCED STAGE CLASSIC HODGKIN LYMPHOMA: PRELIMINARY SAFETY AND EFFICACY RESULTS FROM THE PHASE 2 STUDY (SGN35 027 PART B)
title_fullStr P1089: BRENTUXIMAB VEDOTIN, NIVOLUMAB, DOXORUBICIN, AND DACARBAZINE (AN+AD) FOR ADVANCED STAGE CLASSIC HODGKIN LYMPHOMA: PRELIMINARY SAFETY AND EFFICACY RESULTS FROM THE PHASE 2 STUDY (SGN35 027 PART B)
title_full_unstemmed P1089: BRENTUXIMAB VEDOTIN, NIVOLUMAB, DOXORUBICIN, AND DACARBAZINE (AN+AD) FOR ADVANCED STAGE CLASSIC HODGKIN LYMPHOMA: PRELIMINARY SAFETY AND EFFICACY RESULTS FROM THE PHASE 2 STUDY (SGN35 027 PART B)
title_short P1089: BRENTUXIMAB VEDOTIN, NIVOLUMAB, DOXORUBICIN, AND DACARBAZINE (AN+AD) FOR ADVANCED STAGE CLASSIC HODGKIN LYMPHOMA: PRELIMINARY SAFETY AND EFFICACY RESULTS FROM THE PHASE 2 STUDY (SGN35 027 PART B)
title_sort p1089: brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine (an+ad) for advanced stage classic hodgkin lymphoma: preliminary safety and efficacy results from the phase 2 study (sgn35 027 part b)
topic Posters
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429456/
http://dx.doi.org/10.1097/01.HS9.0000847224.76139.00
work_keys_str_mv AT leeh p1089brentuximabvedotinnivolumabdoxorubicinanddacarbazineanadforadvancedstageclassichodgkinlymphomapreliminarysafetyandefficacyresultsfromthephase2studysgn35027partb
AT flinniw p1089brentuximabvedotinnivolumabdoxorubicinanddacarbazineanadforadvancedstageclassichodgkinlymphomapreliminarysafetyandefficacyresultsfromthephase2studysgn35027partb
AT melearj p1089brentuximabvedotinnivolumabdoxorubicinanddacarbazineanadforadvancedstageclassichodgkinlymphomapreliminarysafetyandefficacyresultsfromthephase2studysgn35027partb
AT ramchandrenr p1089brentuximabvedotinnivolumabdoxorubicinanddacarbazineanadforadvancedstageclassichodgkinlymphomapreliminarysafetyandefficacyresultsfromthephase2studysgn35027partb
AT friedmanj p1089brentuximabvedotinnivolumabdoxorubicinanddacarbazineanadforadvancedstageclassichodgkinlymphomapreliminarysafetyandefficacyresultsfromthephase2studysgn35027partb
AT burkejm p1089brentuximabvedotinnivolumabdoxorubicinanddacarbazineanadforadvancedstageclassichodgkinlymphomapreliminarysafetyandefficacyresultsfromthephase2studysgn35027partb
AT linharesy p1089brentuximabvedotinnivolumabdoxorubicinanddacarbazineanadforadvancedstageclassichodgkinlymphomapreliminarysafetyandefficacyresultsfromthephase2studysgn35027partb
AT ravalm p1089brentuximabvedotinnivolumabdoxorubicinanddacarbazineanadforadvancedstageclassichodgkinlymphomapreliminarysafetyandefficacyresultsfromthephase2studysgn35027partb
AT chintapatlar p1089brentuximabvedotinnivolumabdoxorubicinanddacarbazineanadforadvancedstageclassichodgkinlymphomapreliminarysafetyandefficacyresultsfromthephase2studysgn35027partb
AT feldmanta p1089brentuximabvedotinnivolumabdoxorubicinanddacarbazineanadforadvancedstageclassichodgkinlymphomapreliminarysafetyandefficacyresultsfromthephase2studysgn35027partb
AT yimerh p1089brentuximabvedotinnivolumabdoxorubicinanddacarbazineanadforadvancedstageclassichodgkinlymphomapreliminarysafetyandefficacyresultsfromthephase2studysgn35027partb
AT islasohlmayerm p1089brentuximabvedotinnivolumabdoxorubicinanddacarbazineanadforadvancedstageclassichodgkinlymphomapreliminarysafetyandefficacyresultsfromthephase2studysgn35027partb
AT deana p1089brentuximabvedotinnivolumabdoxorubicinanddacarbazineanadforadvancedstageclassichodgkinlymphomapreliminarysafetyandefficacyresultsfromthephase2studysgn35027partb
AT ranav p1089brentuximabvedotinnivolumabdoxorubicinanddacarbazineanadforadvancedstageclassichodgkinlymphomapreliminarysafetyandefficacyresultsfromthephase2studysgn35027partb
AT gandhimd p1089brentuximabvedotinnivolumabdoxorubicinanddacarbazineanadforadvancedstageclassichodgkinlymphomapreliminarysafetyandefficacyresultsfromthephase2studysgn35027partb
AT renshawj p1089brentuximabvedotinnivolumabdoxorubicinanddacarbazineanadforadvancedstageclassichodgkinlymphomapreliminarysafetyandefficacyresultsfromthephase2studysgn35027partb
AT gillespietwardyal p1089brentuximabvedotinnivolumabdoxorubicinanddacarbazineanadforadvancedstageclassichodgkinlymphomapreliminarysafetyandefficacyresultsfromthephase2studysgn35027partb
AT hol p1089brentuximabvedotinnivolumabdoxorubicinanddacarbazineanadforadvancedstageclassichodgkinlymphomapreliminarysafetyandefficacyresultsfromthephase2studysgn35027partb
AT puhlmannm p1089brentuximabvedotinnivolumabdoxorubicinanddacarbazineanadforadvancedstageclassichodgkinlymphomapreliminarysafetyandefficacyresultsfromthephase2studysgn35027partb
AT guow p1089brentuximabvedotinnivolumabdoxorubicinanddacarbazineanadforadvancedstageclassichodgkinlymphomapreliminarysafetyandefficacyresultsfromthephase2studysgn35027partb
AT yasenchakca p1089brentuximabvedotinnivolumabdoxorubicinanddacarbazineanadforadvancedstageclassichodgkinlymphomapreliminarysafetyandefficacyresultsfromthephase2studysgn35027partb

Ejemplares similares